TITLE

Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis

AUTHOR(S)
Harrison, David J.; Xingyue Huang; Globe, Denise
PUB. DATE
August 2010
SOURCE
American Journal of Health-System Pharmacy;8/1/2010, Vol. 67 Issue 15, p1281
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. Differences in dosing patterns and costs among patients with rheumatoid arthritis (RA) treated with the tumor necrosis factor (TNF) inhibitors etanercept, adalimumab, and infliximab were analyzed on the basis of claims data. Methods. Commercial health insurance claims data from January 2004 through December 2005 from the PharMetrics Patient-centric Database were analyzed. Adults (⩾18 years of age) with RA with a minimum of two claims for the same TNF inhibitor within a 12-month period and with at least 18 months of continuous enrollment in the database (encompassing a 6-month preindex period and a 12-month follow-up period) were included. Patients were considered treatment naive if they had no claims for a TNF inhibitor during the preindex period; continuing patients had at least one TNF-inhibitor claim during the preindex period. Results. A total of 845 treatment-naive and 3783 continuing patients were included. Medication use, costs, and health care use were generally similar among the treatment groups in the preindex period for both naive and continuing patients. Among both naive and continuing patients, dose increases from the first to the last prescription were most likely to occur in the infliximab group (26% and 24%, respectively) compared with the adalimumab (10% and 9%) and etanercept (1% and 3%) groups. Etanercept was associated with the lowest and infliximab with the highest total anti-TNF therapy costs. Anti-TNF-related costs were higher among patients with a high index dose, a dose increase, or both during the follow-up period than among those without. Conclusion. Dose increases with TNF inhibitors commonly occurred in RA patients in the clinical setting and were associated with greater costs of anti-TNF therapy.
ACCESSION #
52449260

 

Related Articles

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics